

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 07-2004)		ATTORNEY'S DOCKET NUMBER PG4791USw
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/509417
INTERNATIONAL APPLICATION NO. PCT/EP03/03339	INTERNATIONAL FILING DATE 27 March 2003	PRIORITY DATE CLAIMED 28 March 2002
TITLE OF INVENTION N-[(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2YL]METHYL-2-{3-[(METHYLSULPHONYL)AMINO]PHENYL}ACETAMIDE AS CCR3 ANTAGONIST FOR THE TREATMENT OF INFLAMMATORY CONDITIONS		
APPLICANT(S) FOR DO/EO/US R. A. Ancliff; C. M. Cook; C. D. Eldred; P. M. Gore; L. A. Harrison; M. A. Hayes; S. T. Hodgson; D. B. Judd; S. E. Keeling; X. Q. Lewell; G. Mills; G. M. Robertson; S. Swanson; A. J. Walker; M. Wilkinson		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). <p>Items 13 to 23 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A power of attorney and/or change of address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 22. <input checked="" type="checkbox"/> Express Mail Label No. <u>EV332062866US</u> 23. <input checked="" type="checkbox"/> Other items or information: <p>Copies of: PCT publication cover page; PCT Request; 20 references listed on the enclosed form PTO-1449 as item nos. 5-13, 15-16 and 19-27</p>		

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.51)

Applicant(s): Rachael Ann ANCLIFF et al.

Docket No. 10/509417

PG4791USw

Serial No. To be assigned	Filing Date Concurrently herewith	Examiner	Group Art Unit
------------------------------	--------------------------------------	----------	----------------

Invention: N-{'(2S)-4-(3,4-DIFLUOROBENZYL)MORPHOLIN-2YL}METHYL-2-{3-'(METHYLSULPHONYL)AMINO-PHENYL}ACETAMIDE AS CCR3 ANTAGONIST FOR THE TREATMENT OF INFLAMMATORY CONDITIONS

I hereby certify that the following correspondence:

U.S. national phase application for patent under 35 USC 371 and accompanying documents

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

September 27, 2004
(Date)

Marjorie J. Pfeiffer

(Typed or Printed Name of Person Mailing Correspondence)

Marjorie J. Pfeiffer
(Signature of Person Mailing Correspondence)

EV332062866US

Note: Each paper must have its own certificate of mailing.